Lower cytokine secretion, potentially reducing the risk of dangerous side effects such as CRS and ICANs, two of the most severe side effects limiting CAR-T and traditional CD3-TCE adoption in ...

Demonstrated potent B-cell depletion and sustained gamma-delta T cell expansion in preclinical studies, offering commercial ...

CD3E, along with CD3-gamma, CD3-delta, CD3-zeta, and T-cell receptor (TCR) alpha/beta or gamma/delta heterodimers, forms the TCR-CD3 complex. This complex is crucial for coupling antigen ...

New York- and Alabama-based IN8bio is leveraging gamma-delta (γδ ... Because our γδ T cells express CD16 and CD3, they can potentially be combined with monoclonal antibodies or bispecifics ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta ... CAR-T and traditional CD3-TCE adoption ...

INB-600 is a novel gamma-delta T cell engager targeting CD19 ... the durability of response and safety compared to existing CD3 targeting TCE therapies. Throughout 2025, we remain focused on ...

A new study published in The Journal of Immunology found that a high-salt diet (HSD) induces depression-like symptoms in mice ...

Reports as of December 31 the company had cash of $11.1M as of December 31, compared with $21.3M as of December 31, 2023. Subsequently, in ...

Compared with healthy and erythrodermic control individuals, the patient’s CD3+ IL-4– and IL-13–secreting cells showed an elevated population of clonal gamma V delta 2 T cells (3.13%).

Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells ...

Demonstrated potent B-cell depletion and sustained gamma-delta T cell expansion in preclinical studies, offering commercial and scientific advantages by potentially improving durability and safety ...